Post by
canadafan on Feb 15, 2024 12:32pm
Latest news very good
The most recent newsprogressing with another phase if the Gobblet trial co- therapy with Roche can only be viewed as good news. Ideally Roche steps up & buys the whole company. It was always noted by management, Majority of acquisitions came on the results of long standing clinical relationships. They certainly have that with Roche. Not to mention the phase 3 fast track approval for the pancreatic cancer co therapy.
Comment by
JohnnyYeg on Feb 15, 2024 1:29pm
AND the FDA has accepted the sBLA (supplemental Biologics Application) and assigned a PDUFA (Prescription Drug User Fee Act) goal date of October 8, 2024
Comment by
Noteable on Feb 15, 2024 2:18pm
" Supplement - A request to FDA to approve a change to an approved license application." FDA Standard Operating Policy and Procedure (SOPP) guideline - SOPP 8401.2: Administrative Processing of BLA and NDA Supplements Version: 10 Effective Date: February 8, 2024 https://www.fda.gov/media/108895/download
Comment by
JohnnyYeg on Feb 15, 2024 2:28pm
Correct Noteable - my bad. It was a misleading link header that used the ONCY ticker symbol and the FDA PDUFA details when in fact the PDUFA mentioned in the article was for Bristol Myers Squibb's section in the article. My apologies folks.
Comment by
lonc17 on Feb 15, 2024 3:19pm
Really if you are doing and expected value calculatoin then you may consdier the possiblility of 20x (or even 30x if bidding war ensues). But MC would need a team of expert negotiators to pull that off.